Using patients insights to move the industry forward
What we do
We work with one of the most important forces in healthcare: the Patient Movement.
PatientView undertakes regular evidence-based research into the different perspectives of patient organisations around the world on a range of issues. PatientView’s reach among these patient organisations is unique, with as many as 40,000 such groups in our informal network.
Patient organisations are in a unique position to provide valuable insights since they are the only stakeholder to interact across every aspect of the healthcare system: from regulators, physicians, healthcare providers, healthcare payers, and of course patients. Patient organisations hold strong views not only about the experiences and needs of patients with whom they are familiar, but on their country’s healthcare policies and systems, the value of technologies (including digital and mobile), and even the reputational status of the various agencies that make healthcare. Across our 20 year history, PatientView has collated evidence-based feedback on all these important subjects. Today, our most high-profile product concerns the corporate reputation of the pharmaceutical industry (from the perspective of patient groups). The product helps pharma develop and improve their strategies to build robust relationships with their ultimate customers, patients - and of course patient groups.
Featured report
What Companies Say
Alongside PatientView's 2023/24 annual survey, pharma provided their own perspectives on patient-group relationships — based on their own experiences, and with their own case studies — as part of this new report.
Latest Blogs
How to take part in PatientView’s 2024 ESG survey
PatientView’s annual, independent ESG study examines patient-group opinions on the pharmaceutical industry’s performance (and that of 40 individual pharma companies) at ESG strategies during 2024, tied to eight key indicators.… Continue reading “How to take part in PatientView’s 2024 ESG survey”
PatientView’s Corporate Reputation of Pharma 2023/24: Insights from Specialised Cancer Patient Groups
July 2024: The field of oncology, cancer research and cancer treatment has seen continued investment over the last few years. In the UK, cancer incidence rates are projected to rise… Continue reading “PatientView’s Corporate Reputation of Pharma 2023/24: Insights from Specialised Cancer Patient Groups”